BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/22/2021 8:09:41 AM | Browse: 521 | Download: 650
 |
Received |
|
2021-04-07 20:28 |
|
Peer-Review Started |
|
2021-04-07 20:31 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-06-15 22:06 |
|
Revised |
|
2021-06-27 14:02 |
|
Second Decision |
|
2021-08-09 02:29 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2021-08-09 06:25 |
|
Articles in Press |
|
2021-08-09 06:25 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2021-09-15 02:42 |
|
Publish the Manuscript Online |
|
2021-09-22 08:09 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Minireviews |
| Article Title |
Atezolizumab and bevacizumab as first line therapy in advanced hepatocellular carcinoma: Practical considerations in routine clinical practice
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Ankit Jain, Shivakumar Chitturi, Geoffrey Peters and Desmond Yip |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Ankit Jain, Visiting Professor, FRACP, MBBS, MD, Staff Physician, Department of Medical Oncology, The Canberra Hospital, Building 19, Level 5, Yamba Drive, Garran 2606, ACT, Australia. ankit.jain@anu.edu.au |
| Key Words |
Hepatocellular carcinoma; Atezolizumab; Bevacizumab; Immunotherapy; Child Pugh cirrhosis; Anti-angiogenic therapy |
| Core Tip |
There are several articles about the role of atezolizumab and bevacizumab combination in advanced unresectable hepatocellular carcinoma. However, this mini review focuses on practical issues for clinicians using this combination in hepatocellular carcinoma (HCC) patients with focus on indications, data from recent trials, criteria’s for selection of appropriate patients for this combination, sequencing strategies, overlapping toxicities, issues with Child Pugh B cirrhosis patients, future role in adjuvant settings and dealing with special subset of HCC population. |
| Publish Date |
2021-09-22 08:09 |
| Citation |
Jain A, Chitturi S, Peters G, Yip D. Atezolizumab and bevacizumab as first line therapy in advanced hepatocellular carcinoma: Practical considerations in routine clinical practice. World J Hepatol 2021; 13(9): 1132-1142 |
| URL |
https://www.wjgnet.com/1948-5182/full/v13/i9/1132.htm |
| DOI |
https://dx.doi.org/10.4254/wjh.v13.i9.1132 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
